Point-Counterpoint: Meningitis/Encephalitis Syndromic Testing in the Clinical Laboratory
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Syndromic panels were first FDA cleared for detection of respiratory pathogens in 2008. Since then, other panels have been approved by the FDA, and most recently, the FilmArray meningitis/encephalitis panel (BioFire, Salt Lake City, UT) has become available. This assay detects 14 targets within 1 h and includes pathogens that typically cause different manifestations of infection, although they infect the same organ system. Several studies have reported both false-positive and false-negative results with this test, and all agree that the cost is significant. As with other panels, health care systems have adopted different strategies for offering this assay. Some have implemented strategies to limit the use of the test to certain patient populations, others have elected not to offer the test, and others have elected not to offer the test and instead request that providers order specific PCRs for the pathogens that best fit the patient's symptoms. In this Point-Counterpoint, Jennifer Dien Bard of the Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, and of the Keck School of Medicine at the University of Southern California explains why laboratories should offer these assays without restriction. Kevin Alby of the University of Pennsylvania explains the concerns about the use of these assays as first-line tests and why some limitations on their use might be appropriate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Leber, A. L., Everhart, K., Balada-Llasat, J.-M., Cullison, J., Daly, J., Holt, S., Lephart, P., Salimnia, H., Schreckenberger, P. C., DesJarlais, S., et al. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00730-16 · Cited by 609 · cited 1×
“This is most evident in cases of viral infections where standard-of-care testing as part of the initial infectious disease workup may be limited to only HSV and enterovirus PCR, missing the more esoteric viral targets (HHV-6, CMV, and HPeV) that may not be high on the list for the differential diagnosis (2, 3).”
BackgroundSelf-citationBuss, S. N., Leber, A., Chapin, K., Fey, P. D., Bankowski, M. J., Jones, M. K., Rogatcheva, M., Kanack, K. J., & Bourzac, K. M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02674-14 · Cited by 554 · cited 1×
“This is most evident in cases of viral infections where standard-of-care testing as part of the initial infectious disease workup may be limited to only HSV and enterovirus PCR, missing the more esoteric viral targets (HHV-6, CMV, and HPeV) that may not be high on the list for the differential diagnosis (2, 3).”
BackgroundCastelblanco, R. L., Lee, M., & Hasbun, R. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70805-9 · Cited by 245
Arora, H. S., Asmar, B. I., Salimnia, H., Agarwal, P., Chawla, S., & Abdel-Haq, N. (2017) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001551 · Cited by 66
Gomez, C. A., Pinsky, B. A., Liu, A., & Banaei, N. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw245 · Cited by 53 · cited 2×
“was identified by conventional testing (4).”
MethodLaunes, C., Casas-Alba, D., Fortuny, C., Valero-Rello, A., Cabrerizo, M., & Muñoz-Almagro, C. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01931-16 · Cited by 26
Cited by
Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae104 · Cited by 376
Tansarli, G. S., & Chapin, K. C. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.016 · Cited by 263
Panels and syndromic testing in clinical microbiology
Dien Bard, J., & McElvania, E. (2020) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2020.08.001 · Cited by 92
An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
“Despite concerns for false-positive and false-negative results, these Biofire ® assays have demonstrated high utility and offer real-time broad detection coverage results [131].”
BackgroundEichinger, A., Hagen, A., Meyer-Bühn, M., & Huebner, J. (2019) · Infection · doi:10.1007/s15010-018-1212-7 · Cited by 60
Metadata
- Authors
- Dien Bard, J., & Alby, K.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2018-04
- Volume
- 56
- Issue
- 4
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2783716598
- Cited by
- 70
- References
- 7
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Point-Counterpoint: Meningitis/Encephalitis Syndromic Testing in the Clinical Laboratory. https://app.cochat.ai/papers/10.1128/jcm.00018-18
- The paper
- Dien Bard, J., & Alby, K. (2018). Point-Counterpoint: Meningitis/Encephalitis Syndromic Testing in the Clinical Laboratory. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00018-18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.